Pimozide NDC 49884-348

NDC codes

FDA NDC Directory

Product NDC (as listed)49884-348Labeler and product segments. Claims need a package NDC.

Product NDC at billing width49884-0348Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
49884-348-01	49884034801	100 TABLET in 1 BOTTLE (49884-348-01)Marketed from Sep 28, 2015

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Pimozide
Generic name (nonproprietary): pimozide
Active ingredients: Pimozide — 2 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Par Health USA, LLC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 204521
Marketing start: Sep 28, 2015
Listing expires: Dec 31, 2027
Identifiers: Product ID 49884-348_a3c5958c-a773-4d10-ae80-9cd453bf07feSPL ID a3c5958c-a773-4d10-ae80-9cd453bf07feSPL set ID 70b079e2-a1f7-4a93-8685-d60a4d7c1280RxCUI 198103, 312439UNII 1HIZ4DL86FUPC 0349884347017, 0349884348014
Pharmacologic class: Typical Antipsychotic

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N449884034801 followed by a unit qualifier and the quantity

Package 49884-0348-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Aug 12, 2026.

Indications (excerpt from the label)

INDICATIONS AND USAGE Pimozide tablets, USP are indicated for the suppression of motor and phonic tics in patients with Tourette’s Disorder who have failed to respond satisfactorily to standard treatment. Pimozide tablets, USP are not intended as a treatment of first choice nor is it intended for the treatment of tics that are merely annoying or cosmetically troublesome. Pimozide tablets, USP should be reserved for use in Tourette’s Disorder patients whose development and/or daily life function is severely compromised by the presence of motor and phonic tics. Evidence supporting approval of pimozide tablets, USP for use in Tourette’s Disorder was obtained in two controlled clinical investiga…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 204521

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 204521
Product	Strength	Form · route	Labeler	Product NDC
Pimozide	Pimozide 1 mg/1	TabletOral	Par Health USA, LLC	49884-347